Flags

Financial distress

Omeros

NMQ:OMER · US6821431029

PharmaceuticalsSmall

360

Medium confidence — indicative

Value48

Profit price48

Cash yield42

Owner Earnings Yield83

Dividend Yield1

Sales & asset price68

Price/Sales39

Price/Book97

Quality43

Returns on capital52

Return on Capital3

Cash Return on Capital100

Profit margins12

Cash backing42

Cash Conversion5

Accruals22

Owner Earnings Margin100

Growth—

Sales growth—

Profit growth65

Reinvestment98

Price momentum88

Safety40

Debt load5

Debt serviceability62

Refinancing84

Debt Payback39

Liquidity36

Sentiment47

Analyst ratings9

Expectations trend53

Opinion Changes5

Price Target Upside100

Market mood23

Value Creation20/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Omeros generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 2/5 components.

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded1994

Employees203

Websiteomeros.com

ISINUS6821431029

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Infectious DiseasesRespiratoryAddictionHematologyImmunologyOncologyCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Omeros Corporation (Omeros) operates as a clinical-stage biopharmaceutical company. The company engages in discovering, developing, and commercializing small-molecule and protein therapeutics for large markets, as well as orphan indications targeting…

Analysis

Middle-of-the-road

Omeros Corporation is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 8.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is mixed and the balance sheet is stretched. The company scores 20/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Omeros with its peers

Neumora Therapeutics

NSQ:NMRA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Harmony Biosciences Holdings

NMQ:HRMY

CountryUSA

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Structure Therapeutics

NMQ:GPCR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Nektar

NAQ:NKTR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

EyePoint

NMQ:EYPT

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

CalciMedica

NAQ:CALC

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →